MedTech Resources

Company

Sight Sciences

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.

Public

Listed

SGHT

Nasdaq · Sight Sciences, Inc.

Public float

$154M

Value of shares held by non-insiders on Jun 30, 2025

Revenue

$77.4M

Fiscal year ending Dec 31, 2025

Net income

-$38.4M

Fiscal year ending Dec 31, 2025

R&D spending

$14.6M

Fiscal year ending Dec 31, 2025

Cash

$77.4M

As of Sep 30, 2026

Long-term debt

$42.4M

As of Sep 30, 2026

Shares outstanding

55.6M

As of Oct 29, 2026

Capital raised as a public company

Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.

YearIPOStock soldLong-term debtConvertible debt
2021$257M–––

Private placements (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
Nov 23, 2020Equity$23.2M$23.2M4Rule 506(b)Form D ↗Dec 10, 2020
Mar 17, 2020Equity$30.2M$30.5M0Rule 506(b)Form D/A ↗Apr 14, 20201 amendment
Aug 9, 2019Equity$30.7M$31.5M2Rule 506(b)Form D/A ↗Sep 10, 20191 amendment
Jul 7, 2017Equity$19.7M$22.2M25Rule 506(b)Form D/A ↗Jun 4, 20181 amendment
Oct 16, 2015Equity$6.9M$7.0M17Rule 506(b)Form D ↗Oct 30, 2015
Sep 12, 2011Equity$525K$5.2M6Rule 506Form D ↗Sep 28, 2011

Company details

From the company's latest Form D.

Legal name
Sight Sciences, Inc.
Headquarters
Menlo Park, California
Incorporated
Delaware over five years before filing
Entity type
Corporation
Revenue range
Decline to Disclose
Industry filed under
Biotechnology

Executives, directors and promoters

As listed on the latest Form D.

  • Paul BadawiExecutive Officer, Director
  • Jesse SelnickExecutive Officer
  • David BadawiDirector
  • Staffan EncrantzDirector
  • Mack HicksDirector
  • Valeska SchroederDirector
  • Erica RogersDirector
  • Andrew OfferDirector
  • Don ZurbayDirector

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

The investor database is part of the paid tier

For Sight Sciences we have 3 shareholders with 5% or more.

It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.

Latest FDA decisions

The 8 newest of 11 since 2015.

Search the Clearance Tracker

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar

Reports received

21

Received Nov 1, 2025 to Nov 19, 2026. Includes 1 of another or unstated type.

Malfunction reports

4

19% of reports

Injury reports

16

76% of reports

Death reports

0

0.0% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 230000
Jan 241100
Feb 240300
Mar 240000
Apr 240200
May 240100
Jun 241100
Jul 240000
Aug 242100
Sep 241100
Oct 241400
Nov 240000
Dec 240000
Jan 250300
Feb 250000
Mar 250000
Apr 251200
May 250100
Jun 250100
Jul 250300
Aug 250000
Sep 250100
Oct 250200
Nov 250100
Dec 251200
Jan 260000
Feb 260000
Mar 260100
Apr 261000
May 261300
Jun 261100
Jul 260200
Aug 260301
Sep 260200
Oct 260100
Nov 260000

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

  • Z-1001-2022 · Started Mar 23, 2022

    Reason given: Ophthalmic devices distributed prior to the recently-obtained 510(k) clearance do not fall within the relevant 510(k) exemption and so their performance characteristics were not evaluated by the FDA prior to distribution.

    Cause as FDA categorized it: No Marketing Application · Device type: Eyelid Thermal Pulsation System (ORZ)

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.